Now part of Stryker.
Feb 25, 2019 - Stryker (NYSE:SYK) announced today it has completed the acquisition of Arrinex, Inc., a medical device company headquartered in Menlo Park, California, that has developed ClariFix®, a novel cryoablation technology for the treatment of chronic rhinitis. Read the full release here.
Expanding Treatment Options for Patients with Chronic Rhinitis
Reviving an ancient technology
Cryotherapy has been used since the time of the ancient Egyptians. Modern cryotherapy is dated back to Dr. Irving Cooper in 1961 and since that time, cryotherapy has been well established in medical literature as safe for soft tissue and nerve ablation.
Cryotherapy is a technique in which freezing cold temperature is used to destroy (or ablate) targeted tissue. Arrinex, Inc. chose cryotherapy to treat patients with chronic rhinitis due to its favorable safety profile.
The area of maximal cryotherapy injury is immediately adjacent to the ClariFix cryoprobe. The zone of effect created (the iceball) grows slowly and has a well-demarcated, sharp boundary.
Another important aspect of cryoablation is that freezing preserves connective tissues. Collagen fibers are highly resistant to freeze injury and are not subject to the denaturation and contraction that can be induced by other thermal-based tissue destruction. Preservation of extracellular matrix and the architecture of nerves, larger blood vessels, and bone provide a scaffold for tissue repair, thereby enabling good tissue healing.
1, 2, 3
1 Sunderland S. “Nerves and Nerve Injuries.” Edinburgh & London: Livingstone (1968): 180.
2 Cooper SM, Dawber RP. The history of cryosurgery. J R Soc Med. Apr;94.4 (2001):196-201.
3 Gage AA, Baust JM, Baust JG. “Experimental cryosurgery investigations in vivo.” Cryobiology 59 (2009):229-243.